Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RCEL vs VVOS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RCEL Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

RCEL Overall Winner 6-Pillar Tally: RCEL 5 – 0 VVOS (1 Tie) Matrix Metrics: RCEL 10 – 0 VVOS

As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RCEL carries a Unified Composite Score of 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin), whereas VVOS carries 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin).

  • Technical & Structure Timing Caution: RCEL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.5); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RCEL vs VVOS
RCEL NASDAQ Head-to-Head Winner
Avita Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.62
-2.31% 1D
Market Cap $506.7M
TTM Revenue $85M
Forward P/E 10.3x
Beta / 30D Vol 1.54β · 65% Vol
Unified Composite Score
45.6 / 100 HOLD
Tech 32.0 Fund 44.0 Flow 69.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (21.1% over 20 days), RSI 52
RSI-14: 51.5 · SMA20: $16.14 · SMA50: $13.96
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13

6-Pillar Scorecard Institutional Category Breakdown (RCEL 5 – 0 VVOS)

Columns: Metric · RCEL · VVOS
1. Valuation Multiples RCEL
Forward P/E 10.3x N/M
Trailing P/E 10.3x N/M
PEG Ratio N/M N/M
EV / Revenue 6.4x 0.1x
2. Growth & Scale RCEL
Revenue Growth (YoY) +53.1% +34.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $85M $21M
Market Cap $506.7M $1.9M
3. Profitability & Quality RCEL
Gross Margin 82.4% 61.9%
Operating Margin -33.9% -107.9%
Net Profit Margin -42.6% -121.8%
Return on Equity (ROE) -1746.3% -8585.3%
4. Balance Sheet & Cash Flow RCEL
Cash Generation (TTM) -$20M -$21M EBITDA
Cash Flow Margin -23.6% -99.3% EBITDA Mgn
Net Cash / Leverage $37M Net Debt -8585.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RCEL
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 84.7% (6th %ile) N/A (N/A)
Put/Call OI Skew 0.18x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RCEL (10) vs VVOS (0)
Institutional Metric RCEL VVOS Criterion Row Edge
Market Capitalization
Scale
$506.7M $1.9M Larger Scale RCEL
Trailing P/E Ratio
Valuation
10.3x N/M Lower Multiple RCEL
Forward P/E Ratio
Valuation
10.3x N/M Lower Multiple RCEL
Revenue Growth (YoY)
Growth
+53.1% +34.9% Higher Growth RCEL
Operating Margin (TTM)
Profitability
-33.9% -107.9% Higher Margin RCEL
Net Profit Margin
Profitability
-42.6% -121.8% Higher Margin RCEL
Return on Equity (ROE)
Capital Efficiency
-1746.3% -8585.3% Higher ROE RCEL
52-Week Range Position
Momentum
82% ($3–$18) 0% ($0–$3) Stronger Trend RCEL
Beta / 30D Volatility
Risk Regime
1.54β · 65% Vol 1.70β · 111% Vol Lower Realized Risk RCEL
Unified Institutional Score
Composite Signal
45.6 / 100 (HOLD) 36.4 / 100 (SELL) Higher Composite RCEL
Trailing 12M Revenue (USD)
Operating Scale
$85M $21M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
82.4% 61.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.4x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$20M ($37M Net Debt) -$21M EBITDA (-8585.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RCEL +60.55 pp
RCEL: +1.3% · VVOS: -59.25%
3M Horizon RCEL +138.11 pp
RCEL: +57.62% · VVOS: -80.49%
6M Horizon RCEL +332.2 pp
RCEL: +241.05% · VVOS: -91.15%
1Y Horizon RCEL +393.15 pp
RCEL: +295.44% · VVOS: -97.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RCEL Revenue VVOS Revenue RCEL Op. Margin VVOS Op. Margin Margin Leader
FY2018 $0M N/A -1489.9% N/A RCEL
FY2019 $10M $10M -466.4% -92.8% VVOS
FY2020 $10M $10M -299.2% -92.1% VVOS
FY2021 $30M $20M -90.8% -120.7% RCEL
FY2022 $30M $20M -79.9% -156.2% RCEL
FY2023 $50M $10M -85.1% -125.3% RCEL
FY2024 $60M $20M -88.1% -74.3% VVOS
FY2025 $70M $20M -59.4% -114.1% RCEL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RCEL CONSOLIDATION
17d in phase · OBV NEUTRAL
Current IV 84.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RCEL Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $506.7M market capitalization and -33.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RCEL vs VVOS Key Questions & Quantitative Answers

As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RCEL carries a Unified Composite Score of 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin), whereas VVOS carries 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin). Technical & Structure Timing Caution: RCEL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.5); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RCEL leads the Growth & Scale pillar: RCEL posts +53.1% YoY revenue growth and +0.0% YoY earnings growth on $85M TTM revenue (82.4% gross margin, -33.9% operating margin), compared with VVOS at +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RCEL cumulative revenue shifted +600.0% while VVOS shifted +100.0%. In operating R&D and SG&A reinvestment, RCEL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VVOS.

RCEL screens cheaper on headline valuation multiples. RCEL trades at 10.3x Forward P/E, 10.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-23.6% FCF margin), whereas VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RCEL (-1746.3% ROE) versus VVOS (-8585.3% ROE) capital efficiency.

In options market volatility and institutional positioning, RCEL carries 84.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.54β · 65% Vol realized risk). By comparison, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.